Kriya Presents Positive Preclinical Data for KRIYA-586 Gene Therapy for TED at ESOPRS Meeting

Kriya Therapeutics, Inc., a biopharmaceutical company focused on gene therapies for common diseases, has shared promising preclinical data on its novel treatment for thyroid eye disease (TED). This data was showcased at the 42nd Annual Meeting of the European Society of Ophthalmic Plastic & Reconstructive Surgery (ESOPRS) in Rotterdam, the Netherlands, from September 12-14, 2024.

The investigational therapy, KRIYA-586, is an adeno-associated virus (AAV) gene therapy designed to deliver an antibody that targets and inhibits the Insulin-Like Growth Factor 1 Receptor (IGF1R). IGF1R plays a crucial role in TED pathogenesis. Presently, the only treatment for TED approved in the U.S. involves an intravenous infusion of a monoclonal antibody that blocks IGF1R. KRIYA-586 aims to simplify this by providing a one-time, localized treatment through a peribulbar injection, minimizing systemic exposure and potentially reducing side effects.

Shankar Ramaswamy, M.D., Co-Founder and CEO of Kriya, expressed enthusiasm about the preclinical results, highlighting the efficacy of KRIYA-586 in inhibiting IGF1R activity. He emphasized the potential of this therapy to meet the unmet medical needs in TED and confirmed plans to advance KRIYA-586 into clinical trials by 2025.

The presentation at ESOPRS detailed the pharmacodynamic activity of KRIYA-586. The data demonstrated the secretion of a human antibody with anti-IGF1R activity in vitro and compared its in vivo pharmacodynamic effects with weekly teprotumumab administration in a humanized xenograft mouse model. The results showed that the vectorized antibody blocked IGF1R as effectively as teprotumumab. Moreover, in preclinical models, the antibody produced by KRIYA-586 significantly reduced IGF1R levels and its downstream activity, similar to teprotumumab.

Kriya has outlined several potential benefits for KRIYA-586 in treating TED:
1. One-time administration: The therapy involves a single in-office peribulbar injection, potentially eliminating the need for multiple intravenous infusions.
2. Focal delivery: The treatment aims for localized antibody expression in the extraocular muscles and fat tissue, reducing systemic exposure and potential side effects.
3. Long-term durability: AAV-mediated expression of the anti-IGF1R antibody may provide sustained improvements in TED symptoms like proptosis and diplopia.

TED is an autoimmune condition characterized by inflammation and swelling of the muscles and fat tissue behind the eyes, leading to symptoms that can severely affect quality of life. The current FDA-approved therapy involves an intravenous monoclonal antibody that blocks IGF1R, highlighting the need for safer and long-lasting treatments for the approximately one million individuals affected by TED in the U.S. and the European Union.

Kriya Therapeutics, with operations in Palo Alto, California, and Research Triangle Park, North Carolina, is dedicated to advancing gene therapies for ophthalmology, metabolic diseases, and neurology. The company has raised over $600 million to support its ambitious pipeline.

Overall, the preclinical data for KRIYA-586 suggests a promising new avenue for treating TED, with plans to proceed to clinical testing in 2025.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!